Autoimmune Disorders

Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

By

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

By

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

By

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

Five things for pharma marketers to know: Thursday, August 18, 2016

Five things for pharma marketers to know: Thursday, August 18, 2016

By

Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled

Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

Fueled by precision medicine, drugmakers delve deeper in autoimmune diseases

By

Drugmakers are working toward developing drugs in lupus, celiac disease, and other conditions that have rarely captured their attention in the past.

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

With competition lurking, Eli Lilly's baricitinib must show unparalled efficacy

By

The bar for market success has been set high for baricitinib.

Top 20 autoimmune products, 2015

Top 20 autoimmune products, 2015

By

AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.

Five things for pharma marketers to know: Thursday, July 9

Five things for pharma marketers to know: Thursday, July 9

By

Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort